Oncology Drugs - Uganda

Uganda

The projected revenue in the Oncology Drugs market in Uganda is expected to reach UGX US$46.37m in 2024.
It is anticipated to show an annual growth rate (CAGR 2024-2029) of 6.74%, leading to a market volume of UGX US$64.25m by 2029.
When compared globally, United States is forecasted to generate the highest revenue of US$103,900.00m in 2024.
Despite facing challenges in healthcare infrastructure, Uganda is seeing an increase in the adoption of innovative oncology drugs to combat the rising cancer burden.

Key regions: France, Europe, United Kingdom, Brazil, India

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Oncology Drugs in Uganda has been increasing steadily over the past few years.

Customer preferences: As the healthcare sector in Uganda continues to develop, patients are becoming more aware of the importance of early detection and treatment of cancer. This has led to an increase in demand for Oncology Drugs as more patients seek treatment options.

Trends in the market: The Oncology Drugs market in Uganda is primarily driven by the increasing prevalence of cancer in the country. The rise in cancer cases can be attributed to factors such as an aging population, changes in lifestyle, and exposure to risk factors such as tobacco and alcohol use. In response to the growing demand for Oncology Drugs, pharmaceutical companies are investing in research and development to introduce new drugs that are more effective in treating cancer.

Local special circumstances: One of the major challenges facing the Oncology Drugs market in Uganda is the high cost of treatment. Many patients are unable to afford the cost of treatment, which limits their access to care. Additionally, the lack of adequate healthcare infrastructure in some parts of the country makes it difficult for patients to access treatment. However, the government has taken steps to address these challenges by investing in healthcare infrastructure and introducing policies aimed at making healthcare more affordable and accessible to all.

Underlying macroeconomic factors: The growth of the Oncology Drugs market in Uganda is also influenced by macroeconomic factors such as GDP growth, government spending on healthcare, and foreign investment. As the economy continues to grow, more resources are being allocated to the healthcare sector, which is driving the development of new drugs and treatment options. Additionally, foreign investment in the pharmaceutical sector is helping to spur innovation and improve access to care for patients in Uganda.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.